TWI625130B - Gel base and gel preparation - Google Patents

Gel base and gel preparation Download PDF

Info

Publication number
TWI625130B
TWI625130B TW104116545A TW104116545A TWI625130B TW I625130 B TWI625130 B TW I625130B TW 104116545 A TW104116545 A TW 104116545A TW 104116545 A TW104116545 A TW 104116545A TW I625130 B TWI625130 B TW I625130B
Authority
TW
Taiwan
Prior art keywords
gel matrix
gel
water
mass
talc
Prior art date
Application number
TW104116545A
Other languages
Chinese (zh)
Other versions
TW201600111A (en
Inventor
松村慎也
中西利博
古瀬靖久
義永隆明
Original Assignee
久光製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 久光製藥股份有限公司 filed Critical 久光製藥股份有限公司
Publication of TW201600111A publication Critical patent/TW201600111A/en
Application granted granted Critical
Publication of TWI625130B publication Critical patent/TWI625130B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本發明係一種凝膠基質,其特徵在於:其係含有選自由3-L-薄荷氧基丙烷-1,2-二醇及3,7-二甲基-2,6-辛二烯-1-醇所組成之群中之至少1種單萜衍生物、水溶性高分子、滑石、醇及水者;且上述單萜衍生物之含量相對於上述凝膠基質之總質量為0.5~10質量%,上述滑石之含量相對於上述凝膠基質之總質量為1.0~6.0質量%。 The present invention is a gel matrix, characterized in that it contains a group selected from 3-L-menthoxypropane-1,2-diol and 3,7-dimethyl-2,6-octadiene-1 -At least one monoterpene derivative, water-soluble polymer, talc, alcohol, and water in the group consisting of alcohol; and the content of the monoterpene derivative relative to the total mass of the gel matrix is 0.5 to 10 mass %, The content of the talc is 1.0 to 6.0% by mass relative to the total mass of the gel matrix.

Description

凝膠基質及凝膠製劑 Gel base and gel preparation

本發明係關於一種凝膠基質及含有其之凝膠製劑。 The invention relates to a gel base and a gel preparation containing the same.

通常,作為施用於皮膚等之外用劑,已知有液劑、軟膏劑、凝膠劑、乳霜劑、霧劑、噴劑等。該等中,凝膠劑(凝膠製劑)係含有添加高分子化合物等凝膠化劑而製成凝膠狀之凝膠基質、及藥物之外用劑,容易直接向患部塗佈等,可謂與其他劑型相比容易操作,又,使用感優異。作為此種凝膠製劑,例如於國際公開第94/26309號(專利文獻1)中記載有調配藥效成分、3-L-薄荷氧基丙烷-1,2-二醇、乙醇等低級醇、水、羧基乙烯基聚合物等凝膠化劑、及三乙醇胺等中和劑而成之凝膠製劑,且記載有上述3-L-薄荷氧基丙烷-1,2-二醇作為有效成分之溶解劑而發揮功能。再者,上述3-L-薄荷氧基丙烷-1,2-二醇通常作為具有帶來清涼感或冷感之作用且皮膚安全性亦較高之化合物而為大眾所知(日本專利特開昭58-88334號公報(專利文獻2)、日本專利特開昭60-25908號公報(專利文獻3))。 In general, as external preparations for application to the skin and the like, liquids, ointments, gels, creams, aerosols, sprays, and the like are known. Among these, gels (gel preparations) include gel bases that are made into gels by adding gelling agents such as polymer compounds, and external preparations for drugs, which are easy to apply directly to the affected area, etc. Compared with other dosage forms, it is easier to handle, and it has an excellent sense of use. As such a gel preparation, for example, in International Publication No. 94/26309 (Patent Document 1), a compounded medicinal ingredient, a lower alcohol such as 3-L-menthoxypropane-1,2-diol, ethanol, A gel preparation made of a gelling agent such as water, a carboxyvinyl polymer, and a neutralizing agent such as triethanolamine, and describes the above 3-L-menthoxypropane-1,2-diol as an active ingredient Function as a dissolving agent. Furthermore, the aforementioned 3-L-menthoxypropane-1,2-diol is generally known as a compound that has a cooling or cooling effect and has high skin safety (Japanese Patent Laid-Open Gazette No. 58-88334 (Patent Document 2) and Japanese Patent Laid-Open No. 60-25908 (Patent Document 3)).

又,已知:以改善上述凝膠製劑之使用感為目的而使凝膠基質含有滑石等粉末材料,從而對凝膠製劑之塗佈部分賦予優異之乾爽感。然而,若使凝膠製劑含有滑石,則具有如下問題:將凝膠製劑塗佈於皮膚並使其乾燥後,產生塗佈部分變白之「白色殘留」。作為以抑制此種白色殘留之產生為目的之凝膠製劑,例如於日本專利特開2011-173823號公報(專利文獻4)中記載有含有特定之水溶性高分子、 滑石、水、脂肪族醇及藥物之凝膠製劑。又,作為以抑制因滑石而引起之白色殘留之產生為目的之基質,日本專利特開2012-87117號公報(專利文獻5)中,作為片狀化妝料中所含之液組合物,記載有以特定比例將包含滑石等粉體及二氧化矽粉體之親水性粉體、特定之側鏈型聚酯改性聚矽氧、及乙醇組合而成之液組合物。 In addition, it is known that, for the purpose of improving the usability of the gel preparation, the gel base contains powder materials such as talc to impart an excellent dryness to the coated portion of the gel preparation. However, if the gel preparation contains talc, there is a problem that after the gel preparation is applied to the skin and dried, a "white residue" in which the applied part turns white occurs. As a gel preparation for the purpose of suppressing the generation of such white residues, for example, Japanese Patent Laid-Open No. 2011-173823 (Patent Document 4) describes the inclusion of specific water-soluble polymers, Gel preparation of talc, water, aliphatic alcohol and medicine. In addition, as a substrate for the purpose of suppressing the generation of white residue caused by talc, Japanese Patent Laid-Open No. 2012-87117 (Patent Document 5) describes a liquid composition contained in a sheet-like cosmetic A liquid composition composed of a hydrophilic powder containing talc and other powders and silica powder, a specific side-chain polyester-modified polysiloxane, and ethanol at a specific ratio.

[先前技術文獻] [Prior Technical Literature] [專利文獻] [Patent Literature]

專利文獻1:國際公開第94/26309號 Patent Literature 1: International Publication No. 94/26309

專利文獻2:日本專利特開昭58-88334號公報 Patent Document 2: Japanese Patent Laid-Open No. 58-88334

專利文獻3:日本專利特開昭60-25908號公報 Patent Document 3: Japanese Patent Laid-Open No. 60-25908

專利文獻4:日本專利特開2011-173823號公報 Patent Document 4: Japanese Patent Laid-Open No. 2011-173823

專利文獻5:日本專利特開2012-87117號公報 Patent Document 5: Japanese Patent Laid-Open No. 2012-87117

然而,本發明者等人認識到:於先前之含有滑石之凝膠製劑之凝膠基質中,若以改善凝膠製劑之使用感為目的而使其以更高濃度含有滑石,則難以充分地抑制白色殘留之產生。又,本發明者等人認識到:於先前之含有滑石及水溶性高分子之凝膠製劑之凝膠基質中,除因上述滑石而引起之白色殘留以外,亦具有如下問題,即,將凝膠製劑塗佈於皮膚並使其乾燥後,容易產生乾燥之高分子於塗佈部分鱗狀地析出之「鱗屑樣物」。 However, the present inventors recognized that in the gel matrix of the previous gel formulation containing talc, it is difficult to sufficiently contain talc in order to improve the sense of use of the gel formulation and to make it contain talc at a higher concentration. Suppresses the generation of white residue. Moreover, the present inventors recognized that in the gel matrix of the previous gel formulation containing talc and a water-soluble polymer, in addition to the white residue caused by the above talc, it also has the following problem, namely, the After the adhesive preparation is applied to the skin and allowed to dry, it is easy to produce "scaly-like substances" where the dried polymer is squamously deposited on the coated part.

本發明係鑒於上述先前技術存在之課題而完成者,其目的在於提供一種可充分地抑制因滑石而引起之白色殘留之產生或因水溶性高分子而引起之鱗屑樣物之產生之凝膠基質、及含有其之凝膠製劑。 The present invention has been completed in view of the above-mentioned problems in the prior art, and its object is to provide a gel matrix capable of sufficiently suppressing the generation of white residue caused by talc or the formation of scale-like substances caused by water-soluble polymers , And gel preparations containing it.

本發明者等人為了達成上述目的而反覆進行銳意研究,結果發 現:藉由使凝膠製劑之凝膠基質中組合含有選自由3-L-薄荷氧基丙烷-1,2-二醇及3,7-二甲基-2,6-辛二烯-1-醇所組成之群中之至少1種單萜衍生物、水溶性高分子、滑石、醇及水,進而以成為特定含量之方式組合上述單萜衍生物及上述滑石,而即便滑石之含量為相對高濃度,亦可充分地抑制因滑石而引起之白色殘留之產生。又,發現:根據此種凝膠基質,亦可充分地抑制因水溶性高分子而引起之鱗屑樣物之產生。 In order to achieve the above purpose, the inventors of the present Now: by combining the gel base of the gel preparation with a combination of 3-L-menthoxypropane-1,2-diol and 3,7-dimethyl-2,6-octadiene-1 -At least one monoterpene derivative, water-soluble polymer, talc, alcohol, and water in the group consisting of alcohol, and then the above monoterpene derivative and the above talc are combined in such a manner as to become a specific content, even if the content of talc is The relatively high concentration can also sufficiently suppress the white residue caused by talc. Furthermore, it was found that such a gel matrix can also sufficiently suppress the generation of scale-like substances caused by water-soluble polymers.

進而,本發明者等人發現藉由提高含有滑石及水溶性高分子之凝膠基質中含有之醇濃度,而有可抑制白色殘留之產生或鱗屑樣物之產生之傾向,但若提高醇濃度,則會產生因醇而引起之對皮膚之刺激增強等問題。相對於此,發現:根據含有上述單萜衍生物之凝膠基質,即便醇濃度為相對低濃度,亦可充分地抑制白色殘留之產生或鱗屑樣物之產生。 Furthermore, the present inventors have found that by increasing the alcohol concentration contained in the gel matrix containing talc and water-soluble polymers, there is a tendency to suppress the generation of white residues or scale-like substances, but if the alcohol concentration is increased , It will cause problems such as increased skin irritation caused by alcohol. On the other hand, it was found that according to the gel matrix containing the above-mentioned monoterpene derivative, even if the alcohol concentration is relatively low, the generation of white residue or the formation of scale-like substances can be sufficiently suppressed.

又,專利文獻4~5中記載有含有與上述3-L-薄荷氧基丙烷-1,2-二醇及3,7-二甲基-2,6-辛二烯-1-醇同樣地為單萜衍生物之1-薄荷腦作為藥物或任意成分。然而,本發明者等人發現:即便使用1-薄荷腦代替3-L-薄荷氧基丙烷-1,2-二醇及/或3,7-二甲基-2,6-辛二烯-1-醇,亦未發揮充分之白色殘留之產生抑制效果及鱗屑樣物之產生抑制效果,該等效果係藉由上述特定之組合而發揮,從而完成本發明。 In addition, Patent Documents 4 to 5 describe the same content as the above 3-L-menthoxypropane-1,2-diol and 3,7-dimethyl-2,6-octadien-1-ol 1-Menthol, a monoterpene derivative, is used as a medicine or any component. However, the present inventors found that even if 1-menthol is used instead of 3-L-menthoxypropane-1,2-diol and / or 3,7-dimethyl-2,6-octadiene- 1-Alcohol also did not exert sufficient white residue generation inhibitory effect and scale-like substance generation inhibitory effect, and these effects were exerted by the specific combination described above, thereby completing the present invention.

即,本發明之凝膠基質係含有選自由3-L-薄荷氧基丙烷-1,2-二醇及3,7-二甲基-2,6-辛二烯-1-醇所組成之群中之至少1種單萜衍生物、水溶性高分子、滑石、醇及水者,且上述單萜衍生物之含量相對於上述凝膠基質之總質量為0.5~10質量%,上述滑石之含量相對於上述凝膠基質之總質量為1.0~6.0質量 %。 That is, the gel matrix of the present invention contains a composition selected from 3-L-menthoxypropane-1,2-diol and 3,7-dimethyl-2,6-octadien-1-ol At least one monoterpene derivative, water-soluble polymer, talc, alcohol and water in the group, and the content of the above monoterpene derivative is 0.5 to 10% by mass relative to the total mass of the above gel matrix. The content is 1.0 ~ 6.0 mass relative to the total mass of the above gel matrix %.

於本發明之凝膠基質中,較佳為,上述單萜衍生物之含量相對於上述凝膠基質之總質量為0.75~5.0質量%。又,較佳為,上述水溶性高分子為選自由水溶性纖維素衍生物及羧基乙烯基聚合物所組成之群中之至少1種。 In the gel matrix of the present invention, preferably, the content of the monoterpene derivative is 0.75 to 5.0% by mass relative to the total mass of the gel matrix. Further, it is preferable that the water-soluble polymer is at least one selected from the group consisting of water-soluble cellulose derivatives and carboxyvinyl polymers.

進而,於本發明之凝膠基質中,較佳為,上述醇為碳數1~3之醇。又,較佳為,上述水溶性高分子之含量相對於上述凝膠基質之總質量為0.5~5.0質量%。 Furthermore, in the gel matrix of the present invention, preferably, the alcohol is an alcohol having 1 to 3 carbon atoms. Moreover, it is preferable that the content of the water-soluble polymer is 0.5 to 5.0% by mass relative to the total mass of the gel matrix.

本發明之凝膠製劑為含有上述本發明之凝膠基質及藥物者。作為本發明之凝膠製劑,較佳為,上述藥物為雙氯芬酸鈉。 The gel preparation of the present invention contains the gel base and the drug of the present invention. As the gel preparation of the present invention, preferably, the above drug is diclofenac sodium.

根據本發明,可提供一種可充分地抑制因滑石而引起之白色殘留之產生或因水溶性高分子而引起之鱗屑樣物之產生之凝膠基質、及含有其之凝膠製劑。 According to the present invention, it is possible to provide a gel matrix capable of sufficiently suppressing the generation of white residue caused by talc or the formation of scale-like substances caused by water-soluble polymers, and a gel preparation containing the same.

圖1係表示對於藉由比較例1、3及4所獲得之凝膠基質進行白色殘留評價試驗之結果之圖表。 FIG. 1 is a graph showing the results of white residue evaluation tests performed on the gel bases obtained in Comparative Examples 1, 3, and 4. FIG.

圖2係表示對於藉由比較例1、3及4所獲得之凝膠基質進行鱗屑樣物評價試驗之結果之圖表。 FIG. 2 is a graph showing the results of a scale-like substance evaluation test performed on the gel matrix obtained in Comparative Examples 1, 3, and 4. FIG.

以下,對本發明依據其較佳之實施形態詳細地進行說明。本發明之凝膠基質之特徵在於:其係含有選自由3-L-薄荷氧基丙烷-1,2-二醇及3,7-二甲基-2,6-辛二烯-1-醇所組成之群中之至少1種單萜衍生物、水溶性高分子、滑石、醇及水者;且上述單萜衍生物之含量相對於上述凝膠基質之總質量為0.5~10 質量%,上述滑石之含量相對於上述凝膠基質之總質量為1.0~6.0質量%。 Hereinafter, the present invention will be described in detail based on its preferred embodiments. The gel matrix of the present invention is characterized in that it contains selected from 3-L-menthoxypropane-1,2-diol and 3,7-dimethyl-2,6-octadien-1-ol At least one monoterpene derivative, water-soluble polymer, talc, alcohol and water in the group formed; and the content of the monoterpene derivative relative to the total mass of the gel matrix is 0.5 to 10 Mass%, the content of the talc is 1.0 to 6.0% by mass relative to the total mass of the gel matrix.

<單萜衍生物> <Monoterpene derivatives>

本發明之單萜衍生物為選自由3-L-薄荷氧基丙烷-1,2-二醇及3,7-二甲基-2,6-辛二烯-1-醇所組成之群中之至少1種。3-L-薄荷氧基丙烷-1,2-二醇通常作為具有帶來清涼感或冷感之作用之化合物而為大眾所知。又,3,7-二甲基-2,6-辛二烯-1-醇(香葉草醇)作為玫瑰油或香葉油之香氣成分而為大眾所知。於本發明中,使包含滑石及水溶性高分子之凝膠基質含有該等特定之單萜衍生物,令人吃驚的是,藉此可充分地抑制因滑石而引起之白色殘留之產生或因水溶性高分子而引起之鱗屑樣物之產生。再者,即便使用例如作為其他單萜衍生物之1-薄荷腦代替本發明之單萜衍生物,亦難以充分地抑制白色殘留之產生或鱗屑樣物之產生。 The monoterpene derivative of the present invention is selected from the group consisting of 3-L-menthoxypropane-1,2-diol and 3,7-dimethyl-2,6-octadien-1-ol At least one of them. 3-L-menthoxypropane-1,2-diol is generally known as a compound having a cooling or cooling effect. In addition, 3,7-dimethyl-2,6-octadien-1-ol (geraniol) is known as a fragrance component of rose oil or geraniol. In the present invention, the gel matrix containing talc and water-soluble polymer contains these specific monoterpene derivatives. Surprisingly, this can sufficiently suppress the generation or cause of white residue caused by talc The generation of scale-like substances caused by water-soluble polymers. Furthermore, even if, for example, 1-menthol, which is another monoterpene derivative, is used instead of the monoterpene derivative of the present invention, it is difficult to sufficiently suppress the generation of white residues or the formation of scale-like substances.

作為本發明之單萜衍生物,既可單獨使用選自由3-L-薄荷氧基丙烷-1,2-二醇及3,7-二甲基-2,6-辛二烯-1-醇所組成之群中之任1種,亦可組合2種以上而使用,但就更加充分地抑制因滑石而引起之白色殘留之產生或因水溶性高分子而引起之鱗屑樣物之產生之觀點而言,更佳為使用3-L-薄荷氧基丙烷-1,2-二醇。 As the monoterpene derivative of the present invention, it can be used alone selected from 3-L-menthoxypropane-1,2-diol and 3,7-dimethyl-2,6-octadien-1-ol Any one of the groups can be used in combination of two or more, but the viewpoint of white residue caused by talc or scale-like substances caused by water-soluble polymers is more fully suppressed In particular, it is more preferable to use 3-L-menthoxypropane-1,2-diol.

於本發明之凝膠基質中,作為本發明之單萜衍生物之含量(3-L-薄荷氧基丙烷-1,2-二醇之含量及/或3,7-二甲基-2,6-辛二烯-1-醇之含量之合計),相對於上述凝膠基質之總質量必須為0.5~10質量%。於上述單萜衍生物之含量未達上述下限之情形時,難以充分地抑制白色殘留之產生及鱗屑樣物之產生。另一方面,於超過上述上限之情形時,會產生黏膩感、或因添加滑石而損壞乾爽感。 In the gel matrix of the present invention, as the content of the monoterpene derivative of the present invention (3-L-menthoxypropane-1,2-diol content and / or 3,7-dimethyl-2, The total content of 6-octadien-1-ol) must be 0.5 to 10% by mass relative to the total mass of the above gel matrix. When the content of the above-mentioned monoterpene derivative does not reach the above lower limit, it is difficult to sufficiently suppress the generation of white residue and the generation of scale-like substances. On the other hand, when the above upper limit is exceeded, a sticky feeling may occur, or dryness may be damaged by the addition of talc.

又,作為上述單萜衍生物之含量,尤佳為相對於上述凝膠基質 之總質量為0.75~5.0質量%。若上述單萜衍生物之含量為上述下限以上,則有可更加充分地抑制白色殘留之產生及鱗屑樣物之產生之傾向。另一方面,若上述單萜衍生物之含量超過上述上限,則有產生黏膩感而乾爽感降低,或乾燥變慢之傾向。 Moreover, as the content of the above-mentioned monoterpene derivative, it is particularly preferable that it is relative to the above-mentioned gel matrix The total mass is 0.75 ~ 5.0 mass%. If the content of the above-mentioned monoterpene derivative is more than the above-mentioned lower limit, there is a tendency that the generation of white residues and scale-like substances can be more fully suppressed. On the other hand, if the content of the above-mentioned monoterpene derivative exceeds the above-mentioned upper limit, there is a tendency to produce a sticky feeling and reduce the dry feeling, or the drying becomes slow.

<水溶性高分子> <Water-soluble polymer>

水溶性高分子係於凝膠基質中作為用以形成凝膠之凝膠化劑而發揮功能者。於本發明中,作為上述水溶性高分子,就即便於對凝膠基質組合作為藥學上可容許之鹽之藥物而製成凝膠製劑之情形時,亦可更佳地使凝膠基質凝膠化,又,即便於上述藥物之總量較多之情形時,亦有容易獲得更良好之流動特性(尤其為延展性、防止滴落)之凝膠製劑之傾向之觀點而言,2質量%水溶液之20℃下之黏度較佳為1,000~280,000mPa‧s,更佳為1,000~30,000mPa‧s。再者,於本發明中,上述黏度係依照日本藥典之規定使用布氏黏度計所測定之值。 The water-soluble polymer functions in the gel matrix as a gelling agent for forming a gel. In the present invention, as the above water-soluble polymer, even when a gel preparation is prepared by combining a drug that is a pharmaceutically acceptable salt with a gel matrix, the gel matrix gel can be made better In addition, even in the case where the total amount of the above drugs is large, there is a tendency to easily obtain a gel formulation with better flow characteristics (especially ductility, drip prevention), 2% by mass The viscosity of the aqueous solution at 20 ° C is preferably 1,000 to 280,000 mPa‧s, more preferably 1,000 to 30,000 mPa‧s. Furthermore, in the present invention, the above-mentioned viscosity is a value measured using a Brookfield viscometer in accordance with the provisions of the Japanese Pharmacopoeia.

作為本發明之水溶性高分子,可適當地使用先前作為上述凝膠化劑而使用者,並無特別限定,就可達成上述較佳之黏度及良好之觸變性,充分地減輕「緊繃感」之觀點而言,較佳為選自由水溶性纖維素衍生物及羧基乙烯基聚合物所組成之群中之至少1種,更佳為選自由水溶性纖維素衍生物所組成之群中之至少1種。 As the water-soluble polymer of the present invention, a user who has previously used the above-mentioned gelling agent can be suitably used, and without particular limitation, the above-mentioned preferable viscosity and good thixotropy can be achieved, and the "tightness" can be sufficiently reduced From a viewpoint, it is preferably at least one selected from the group consisting of water-soluble cellulose derivatives and carboxyvinyl polymers, and more preferably at least one selected from the group consisting of water-soluble cellulose derivatives 1 kind.

通常,於含有水溶性高分子之凝膠基質於皮膚上乾燥而形成皮膜時,由於變乾過程中該皮膜會收縮,因此會使皮膚產生不舒服之「緊繃感」。此時,若使用分子量較大,容易結晶化之水溶性高分子,則由於構成皮膜之水溶性高分子之物理強度變得更大,因此會產生更強之緊繃感。再者,上述容易結晶化之水溶性高分子通常為直鏈狀且分子之對稱性較高,具有極性官能基之高分子,為結晶化性較高之高分子。相對於此,上述水溶性纖維素衍生物及羧基乙烯基聚合物 由於為結晶化性相對較低之高分子,因此有可進一步減輕緊繃感之傾向。 Generally, when a gel matrix containing a water-soluble polymer is dried on the skin to form a skin film, the skin film shrinks during the drying process, thereby causing an uncomfortable "tightness" to the skin. At this time, if a water-soluble polymer having a large molecular weight and easy to crystallize is used, the physical strength of the water-soluble polymer constituting the film becomes greater, so a stronger sense of tightness is generated. Furthermore, the water-soluble polymer that is easily crystallized is usually linear and has high symmetry of the molecule, and a polymer having a polar functional group is a polymer with high crystallinity. In contrast, the above water-soluble cellulose derivatives and carboxyvinyl polymers Since it is a polymer with relatively low crystallinity, it tends to further reduce the tightness.

作為上述水溶性纖維素衍生物,例如可列舉羥乙基纖維素、羥丙基纖維素、甲基纖維素、乙基纖維素、羧甲基纖維素、羥丙基甲基纖維素(羥丙甲纖維素),既可單獨使用該等中之1種,亦可組合2種以上而使用。其中,作為上述水溶性纖維素衍生物,較佳為使用羥丙基甲基纖維素或羥丙基纖維素之任一者,更佳為使用羥丙基纖維素。 Examples of the water-soluble cellulose derivatives include hydroxyethyl cellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, carboxymethyl cellulose, and hydroxypropyl methyl cellulose (hydroxypropyl cellulose). (Methyl cellulose) may be used alone or in combination of two or more. Among them, as the water-soluble cellulose derivative, either hydroxypropyl methyl cellulose or hydroxypropyl cellulose is preferably used, and hydroxypropyl cellulose is more preferably used.

上述羥丙基甲基纖維素(羥丙甲纖維素)係對於纖維素之單元糖結構(葡萄糖)之3個羥基局部地導入羥基丙氧基及甲氧基作為取代基而成者。該等取代基係對於上述纖維素之單元糖結構之羥基被不規則地導入。藉由以此方式局部地、不規則地導入有2種取代基,上述羥丙基甲基纖維素之分子結構之規則性降低而成為高分子之結晶化性較低者,因此有凝膠基質乾燥而形成之皮膜之強度變小,上述緊繃感進一步減輕之傾向。 The hydroxypropyl methyl cellulose (hypromellose) is obtained by partially introducing hydroxypropoxy and methoxy groups as substituents to the three hydroxyl groups of the unit sugar structure (glucose) of cellulose. These substituents are introduced irregularly to the hydroxyl group of the unit sugar structure of the cellulose. By introducing two kinds of substituents locally and irregularly in this way, the regularity of the molecular structure of the above hydroxypropyl methylcellulose is reduced and it becomes a polymer with lower crystallinity, so there is a gel matrix The strength of the film formed by drying becomes smaller, and the above-mentioned tight feeling tends to be further reduced.

作為此種羥丙基甲基纖維素,較佳為,羥基丙氧基之取代度為4.0~32.0%,且甲氧基之取代度為16.5~30.0%之範圍,更佳為,羥基丙氧基之取代度為4.0~12.0%,且甲氧基之取代度為22.0~30.0%。若上述取代度為該範圍內,則有凝膠之流動特性變得更佳之傾向,進而於凝膠基質包含藥物時,有發揮較佳之藥物之治療效果之傾向。 As such hydroxypropyl methylcellulose, it is preferred that the degree of substitution of hydroxypropoxy is 4.0 to 32.0%, and the degree of substitution of methoxy is 16.5 to 30.0%, more preferably, hydroxypropoxy The substitution degree of the group is 4.0 ~ 12.0%, and the substitution degree of the methoxy group is 22.0 ~ 30.0%. If the degree of substitution is within this range, the flow characteristics of the gel tend to be better, and when the gel matrix contains a drug, there is a tendency to exert a better therapeutic effect of the drug.

又,上述羥丙基纖維素係對於纖維素之單元糖結構(葡萄糖)之3個羥基局部地導入羥基丙氧基作為取代基而成者。該取代基係對於上述纖維素之單元糖結構之羥基被不規則地導入。藉由以此方式局部地、不規則地導入有取代基,上述羥丙基纖維素之分子結構之規則性降低而成為高分子之結晶化性較低者,因此有凝膠基質乾燥而形成之皮膜之強度變小,上述緊繃感減輕之傾向。作為上述羥丙基纖維素中 之羥基丙氧基之取代度,較佳為50~80%。又,於本發明中,作為上述羥丙基纖維素之2質量%水溶液之20℃下之黏度,較佳為1,000~4,000mPa‧s。 In addition, the hydroxypropyl cellulose is obtained by partially introducing hydroxypropoxy groups as substituents to the three hydroxyl groups of the unit sugar structure (glucose) of cellulose. The substituent is introduced irregularly to the hydroxyl group of the unit sugar structure of the cellulose. By introducing substituents locally and irregularly in this way, the regularity of the molecular structure of the above hydroxypropyl cellulose is reduced to become a polymer with lower crystallinity, so the gel matrix is formed by drying The strength of the film becomes smaller, and the above-mentioned feeling of tightness tends to be reduced. As the above hydroxypropyl cellulose The substitution degree of the hydroxypropoxy group is preferably 50 to 80%. In the present invention, the viscosity at 20 ° C. of the 2% by mass aqueous solution of the hydroxypropyl cellulose is preferably 1,000 to 4,000 mPa‧s.

上述羧基乙烯基聚合物係具有以聚丙烯酸為主鏈而局部地交聯而成之交聯結構之高分子。上述羧基乙烯基聚合物由於以此方式交聯且分子量極大,因此可藉由少量之添加而使凝膠基質增黏,就延展性之提高、滴落之防止、及防止於將凝膠基質塗佈於皮膚時因凝膠基質中之固形物成分而產生垢狀之塊、即「結塊」之觀點而言較佳。又,由於上述交聯結構為局部性,因此有凝膠基質乾燥而形成之皮膜之強度變小,上述緊繃感減輕之傾向。 The carboxyvinyl polymer is a polymer having a cross-linked structure partially cross-linked with polyacrylic acid as the main chain. The above-mentioned carboxyvinyl polymer is cross-linked in this way and has a very high molecular weight, so the gel matrix can be thickened by a small amount of addition to improve the ductility, prevent dripping, and prevent the gel matrix from being coated. From the viewpoint of the formation of scale-like masses due to the solid content of the gel matrix when it is applied to the skin, that is, "caking" is preferred. In addition, since the cross-linked structure is local, the strength of the film formed by drying the gel matrix tends to decrease, and the tightness tends to be reduced.

於使用上述羧基乙烯基聚合物之情形時,就藉由中和羧基而發揮更高之增黏性之觀點而言,於製造上述凝膠基質時,較佳為與上述羧基乙烯基聚合物一併調配用以進行上述中和之中和劑。作為上述中和劑,並無特別限定,較佳為使用氨水、氫氧化鈉、二異丙醇胺、二(2-乙基己基)胺、三乙醇胺及三乙基胺等有機胺。 In the case of using the above carboxyvinyl polymer, from the viewpoint of exerting higher viscosity increase by neutralizing the carboxyl group, when manufacturing the above gel matrix, it is preferable to And formulated to carry out the above neutralizing agent. The neutralizing agent is not particularly limited, but organic amines such as ammonia water, sodium hydroxide, diisopropanolamine, di (2-ethylhexyl) amine, triethanolamine, and triethylamine are preferably used.

於本發明中,作為上述羧基乙烯基聚合物之0.2質量%水溶液(pH值7~7.5)之20℃下之黏度,較佳為5,000mPa‧s~29,000mPa‧s,更佳為5,000mPa‧s~28,000mPa‧s,進而較佳為6,000mPa‧s~14,000mPa‧s。 In the present invention, the viscosity at 20 ° C of the 0.2% by mass aqueous solution (pH value 7 to 7.5) of the above carboxyvinyl polymer is preferably 5,000 mPa‧s to 29,000 mPa‧s, more preferably 5,000 mPa‧ s ~ 28,000mPa‧s, further preferably 6,000mPa‧s ~ 14,000mPa‧s

於本發明之凝膠基質中,作為本發明之水溶性高分子之含量(於2種以上之情形時,為各水溶性高分子之含量之合計),相對於上述凝膠基質之總質量,較佳為0.5~5.0質量%,更佳為2.0~4.0質量%。又,於使用上述水溶性纖維素衍生物作為本發明之水溶性高分子之情形時,作為其含量,相對於上述凝膠基質之總質量,較佳為0.5~5.0質量%,更佳為2.0~4.0質量%。若上述水溶性高分子之含量為該範圍內,則有如下傾向:凝膠基質之增黏性及流動性變得更佳而可充分 地抑制滴落或結塊之產生。 In the gel matrix of the present invention, as the content of the water-soluble polymer of the present invention (in two or more cases, the total content of each water-soluble polymer), relative to the total mass of the gel matrix, It is preferably 0.5 to 5.0% by mass, and more preferably 2.0 to 4.0% by mass. In addition, when the above water-soluble cellulose derivative is used as the water-soluble polymer of the present invention, the content thereof is preferably 0.5 to 5.0% by mass relative to the total mass of the above gel matrix, and more preferably 2.0 ~ 4.0% by mass. If the content of the water-soluble polymer is within this range, there is a tendency that the viscosity and fluidity of the gel matrix become better and sufficient To suppress dripping or agglomeration.

作為本發明之水溶性高分子之含量,於使用具有上述黏度特性之水溶性高分子之情形時,藉由調配相對較少之黏度相對較高之上述水溶性高分子,而有如下傾向:乾燥變得更快,或可充分地抑制結塊之產生。 As the content of the water-soluble polymer of the present invention, when a water-soluble polymer having the above-mentioned viscosity characteristics is used, by formulating the relatively small amount of the above-mentioned water-soluble polymer having a relatively high viscosity, there is a tendency to dry as follows: Become faster, or can sufficiently suppress the formation of lumps.

又,若使用上述水溶性纖維素衍生物作為上述水溶性高分子,則有尤其容易產生鱗屑樣物之傾向,但於本發明中,以相對高濃度(例如,相對於上述凝膠基質之總質量為3.0質量%以上(更具體而言,例如為3.0~5.0質量%))使用此種水溶性纖維素衍生物,亦可充分地抑制鱗屑樣物之產生。 In addition, if the above-mentioned water-soluble cellulose derivative is used as the above-mentioned water-soluble polymer, it tends to be particularly likely to produce scale-like substances. However, in the present invention, a relatively high concentration (e.g., relative to the total The mass is 3.0% by mass or more (more specifically, for example, 3.0 to 5.0% by mass)) Using such a water-soluble cellulose derivative can also sufficiently suppress the generation of scale-like substances.

<滑石> <Talc>

本發明之滑石係具有調節凝膠基質之流動特性之功能,且於將凝膠基質塗佈於皮膚等後可對該塗佈部位賦予乾爽感之粉末成分。再者,推測此種乾爽感係因如下而達成:於皮膚上含有上述水溶性高分子之凝膠基質乾燥而形成之皮膜被上述滑石擦過,其結果,於皮膜上形成大量脆弱部而皮膜之強度變小,上述緊繃感減輕。 The talc of the present invention has a function of adjusting the flow characteristics of the gel matrix, and after applying the gel matrix to the skin or the like, it can give a dry feeling to the coated part. Furthermore, it is presumed that this dry feeling is achieved by the following: the film formed by drying the gel matrix containing the water-soluble polymer on the skin is rubbed by the talc, and as a result, a large number of fragile parts are formed on the film and the film The strength becomes smaller and the above-mentioned feeling of tightness is reduced.

作為本發明之滑石,可列舉將滑石(Mg3Si4O10(OH)2)粉碎而獲得之天然之含水矽酸鎂。此種滑石被分類為層狀矽酸鹽礦物,其晶體結構為如下結構,即,將於以SiO4四面體為重複單元之2層之間夾著以Mg(OH)2八面體為重複單元之層而三明治狀地層疊之結構作為基本結構,進而使該基本結構層狀地積層而成之結構。由於該三明治狀之各層之間之相互之結合僅為凡得瓦力,因此滑石具有容易產生解理,容易崩解之特性,因此莫氏硬度與其他礦物相比較小。因此推測:與其他礦物相比,可賦予上述優異之乾爽感。 Examples of the talc of the present invention include natural hydrous magnesium silicate obtained by pulverizing talc (Mg 3 Si 4 O 10 (OH) 2 ). This type of talc is classified as a layered silicate mineral, and its crystal structure is as follows, that is, Mg (OH) 2 octahedral is repeated between 2 layers with SiO 4 tetrahedron as the repeating unit. The structure in which the layers of the units are laminated in a sandwich shape is regarded as the basic structure, and the basic structure is laminated in layers. Because the combination of the sandwich-shaped layers is only Van der Waals, talc has the characteristics of easy cleavage and easy disintegration, so the Mohs hardness is smaller than other minerals. Therefore, it is speculated that, compared with other minerals, the above-mentioned excellent dry feeling can be imparted.

作為此種滑石粉末之粒徑,就可賦予更加光滑之觸感,且容易附著於皮膚之觀點而言,較佳為以體積基準平均粒徑計處於1~30μm 之範圍內。再者,於本發明中,上述體積基準平均粒徑係自使用雷射繞射式粒度分佈測定裝置而獲得之體積基準之粒徑分佈而求出。 The particle size of such talc powder is preferably 1-30 μm in terms of volume-based average particle size from the viewpoint of providing a smoother touch and being easy to adhere to the skin. Within. Furthermore, in the present invention, the volume-based average particle size is obtained from a volume-based particle size distribution obtained by using a laser diffraction particle size distribution measuring device.

於本發明之凝膠基質中,作為本發明之滑石之含量,相對於上述凝膠基質之總質量必須為1.0~6.0質量%。於上述滑石之含量未達上述下限之情形時,無法充分地發揮賦予乾爽感,減輕黏膩性,使凝膠基質容易塗開等滑石之效果。另一方面,於超過上述上限之情形時,難以將凝膠基質塗開,或產生粗糙感。又,作為上述滑石之含量,就有更加充分地抑制黏膩性之影響,使塗開變得容易,可防止粗糙感之產生之傾向之觀點而言,尤佳為相對於上述凝膠基質之總質量為3.0~5.0質量%。再者,若使用上述滑石,則有尤其容易產生白色殘留之傾向,但於本發明中,即便以高濃度(例如,相對於上述凝膠基質之總質量為4.0質量%以上(更具體而言,例如為4.0~6.0質量%))使用此種滑石,亦可充分地抑制白色殘留之產生。 In the gel matrix of the present invention, the content of talc of the present invention must be 1.0 to 6.0% by mass relative to the total mass of the gel matrix. When the content of the talc does not reach the above lower limit, the effects of imparting dryness, reducing stickiness, and making the gel matrix easy to spread, etc. cannot be fully exerted. On the other hand, when the above upper limit is exceeded, it is difficult to spread the gel matrix or produce a rough feeling. In addition, as the content of the above-mentioned talc, the effect of more adequately suppressing the stickiness, making it easier to spread, and preventing the tendency of roughness is particularly preferable to the above-mentioned gel matrix. The total mass is 3.0 ~ 5.0 mass%. In addition, if the above-mentioned talc is used, there is a tendency to produce white residues in particular, but in the present invention, even at a high concentration (for example, the total mass of the gel matrix is 4.0% by mass or more (more specifically , For example, 4.0 to 6.0% by mass)) Use of such talc can also sufficiently suppress the occurrence of white residue.

<醇、水> <Alcohol, water>

醇及水係於凝膠基質中作為形成水溶性高分子與凝膠之液性介質而發揮功能者。於本發明中,作為上述醇,並無特別限定,但就若碳數變多則有乾燥變慢之傾向之觀點而言,較佳為碳數1~3之醇。作為上述碳數1~3之醇,例如可列舉乙醇、異丙醇,既可單獨使用該等中之1種,亦可組合2種以上而使用。 Alcohol and water function as a liquid medium that forms a water-soluble polymer and a gel in the gel matrix. In the present invention, the above-mentioned alcohol is not particularly limited, but from the viewpoint of increasing the number of carbons, drying tends to be slow, and alcohols having 1 to 3 carbons are preferred. Examples of the alcohols having 1 to 3 carbon atoms include ethanol and isopropanol. One of these may be used alone, or two or more of them may be used in combination.

作為上述醇之含量,並無特別限定,相對於上述凝膠基質之總質量,較佳為30~95質量%,更佳為40~90質量%,進而較佳為60~85質量%。若上述醇之含量未達上述下限,則有乾燥變慢或容易結塊之傾向,另一方面,若超過上述上限,則有因醇而引起之對皮膚之刺激增強之傾向。再者,本發明者等人發現藉由提高含有滑石及水溶性高分子之凝膠基質中含有之醇濃度,有可抑制白色殘留之產生或鱗屑樣物之產生之傾向,但於本發明中,即便醇濃度為相對低濃度(例 如,相對於上述凝膠基質之總質量為40質量%以下(更具體而言,例如為30~40質量%)),亦可充分地抑制白色殘留之產生或鱗屑樣物之產生,因此可提供皮膚刺激較少之凝膠基質。 The content of the alcohol is not particularly limited, and is preferably 30 to 95% by mass, more preferably 40 to 90% by mass, and still more preferably 60 to 85% by mass relative to the total mass of the gel matrix. If the content of the alcohol does not reach the above lower limit, drying tends to slow down or lumps easily, on the other hand, if it exceeds the above upper limit, the skin irritation caused by alcohol tends to increase. Furthermore, the present inventors have found that by increasing the concentration of alcohol contained in the gel matrix containing talc and water-soluble polymers, there is a tendency to suppress the generation of white residues or scale-like substances, but in the present invention , Even if the alcohol concentration is relatively low (eg For example, with respect to the total mass of the gel matrix being 40% by mass or less (more specifically, for example, 30 to 40% by mass), the occurrence of white residues or scale-like substances can also be sufficiently suppressed, so it is possible Provides a gel base with less skin irritation

作為上述水,較佳為實施離子交換、蒸餾、過濾等純化後之水,例如可較佳地使用日本藥典(日本藥典第十五修訂版)中所記載之「純化水」。作為此種水之含量,並無特別限定,相對於上述凝膠基質之總質量,較佳為1.0~59.5質量%,更佳為1.0~40.0質量%。 The water is preferably water after purification such as ion exchange, distillation, and filtration, and for example, "purified water" described in the Japanese Pharmacopoeia (15th revised edition of the Japanese Pharmacopoeia) can be preferably used. The content of such water is not particularly limited, and it is preferably 1.0 to 59.5 mass%, more preferably 1.0 to 40.0 mass% relative to the total mass of the gel matrix.

作為本發明之凝膠基質,除上述單萜衍生物、上述水溶性高分子、上述滑石、上述醇、及上述水以外,亦可於不阻礙本發明之效果之範圍內,視需要進而含有上述滑石以外之粉末成分、油成分、香料、顏料、穩定化劑、吸收促進劑等添加劑。 As the gel matrix of the present invention, in addition to the above-mentioned monoterpene derivative, the above-mentioned water-soluble polymer, the above-mentioned talc, the above-mentioned alcohol, and the above-mentioned water, it may further contain the above-mentioned as needed within the range not hindering the effect of the present invention Powder ingredients other than talc, oil ingredients, fragrances, pigments, stabilizers, absorption accelerators and other additives.

<藥物> <Medicine>

本發明之凝膠製劑之特徵在於含有上述本發明之凝膠基質、及藥物。作為可用於本發明之凝膠製劑之藥物,並無特別限定,可列舉:例如鹽酸布替萘芬、鹽酸特比萘芬、萘替芬、鹽酸阿莫羅芬、鹽酸奈康唑、盧力康唑、拉諾康唑、硝酸肟可納唑、酮康唑、硝酸咪可納唑、噻康唑、聯苯苄唑、克氯黴唑、硝酸亦可那唑、伊曲康唑、氟康唑等抗真菌藥;例如吲哚美辛、酮洛芬、聯苯乙酸、氟比洛芬、雙氯芬酸鈉、氯索洛芬、布洛芬、布洛芬吡甲酯、瓜[甘菊]薁、尿囊素、甘草酸、甘草次酸、水楊酸、水楊酸甲酯、單水楊酸乙二醇等消炎止痛藥(抗炎症藥);例如介質游離抑制劑(曲尼司特、色甘酸鈉)、組織胺H1受體拮抗劑(奧沙米特、過敏美奎錠、依美斯汀、依巴斯汀、氯雷他定、西替利嗪、地氯雷他定、非索非那定、阿司咪唑、氮卓斯汀、氯菲安明、苯海拉明、可多替芬)、組織胺H2受體拮抗劑(希美替定、雷尼替定、啡莫替定、尼紮替丁)、組織胺H3受體拮抗劑(噻普醯胺、英普咪定、咪芬替丁、伊姆他胺、氯氮平)、組織胺H4受體 拮抗劑等抗組織胺藥;例如1-薄荷腦、樟腦、冰片、丁香酚、桉油、薄荷油、丁香油、桂皮油、茶樹油等精油成分;例如異丙基甲基苯酚、葡萄糖酸雙氯苯雙胍己啶、利凡諾、鹽酸苄烷銨等殺菌藥;例如鹽酸待布卡因、鹽酸利多卡因、鹽酸普魯卡因、鹽酸四卡因、鹽酸布比卡因、鹽酸丙胺卡因、鹽酸奧布卡因、鹽酸甲哌卡因、奧昔卡因等局部麻醉藥;例如克羅米通、魚石脂、Mocthammol、百里香酚酸等止癢劑;例如辣椒萃取成分、辣椒素、壬酸香草醯胺等血流促進劑;例如戊酸地塞米松、戊酸乙酸地塞米松、丙酸地塞米松、乙酸潑尼松龍、戊酸乙酸潑尼松龍、潑尼松龍、丁酸丙酸氫化可體松、乙酸氫化可體松、丁酸氫化可體松、乙酸可體松、丁酸可洛貝他松、曲安奈德、戊酸雙氟可龍、二氟孕甾丁酯、乙酸二氟拉松酯、二丙酸倍他米松、安西奈德、哈西奈德、布地奈德、二丙酸阿氯米松等類固醇激素;以及該等之藥學上可容許之鹽(於上述藥物為鹽之情形時,為其他鹽)及於上述藥物為鹽之情形時之其游離物,既可單獨使用該等中之1種,亦可組合2種以上而使用。 The gel preparation of the present invention is characterized by containing the above-mentioned gel matrix of the present invention and a drug. The drug that can be used in the gel preparation of the present invention is not particularly limited, and examples include butenafine hydrochloride, terbinafine hydrochloride, naftifine, amorolfine hydrochloride, neconazole hydrochloride, luliconazole , Lanoconazole, oxime konconazole nitrate, ketoconazole, miconazole nitrate, ticonazole, bifonazole, clotrimazole, canaconazole nitrate, itraconazole, fluconazole And other antifungal drugs; for example indomethacin, ketoprofen, biphenylacetic acid, flurbiprofen, diclofenac sodium, loxoprofen, ibuprofen, ibuprofen methyl ester, melon [camomile] azulene, Allantoin, glycyrrhizic acid, glycyrrhetinic acid, salicylic acid, methyl salicylate, ethylene glycol monosalicylate and other anti-inflammatory analgesics (anti-inflammatory drugs); for example, mediator free inhibitors (tranilast, color Sodium Glycinate), Histamine H1 Receptor Antagonist (Oxamid, Allergic Meguidine, Emestatin, Ebastine, Loratadine, Cetirizine, Deloratadine, Fexo Phenadine, astemizole, azelastine, clofiphenamine, diphenhydramine, codotifen), histamine H2 receptor antagonists (simetidine, ranitidine, phenmotidine , Nizatidine), histamine H3 receptor antagonists (tipamide, imprimidine, mifentidine, imatinamide, clozapine), histamine H4 receptor Antihistamines such as antagonists; for example, 1-menthol, camphor, borneol, eugenol, eucalyptus oil, peppermint oil, clove oil, cassia oil, tea tree oil and other essential oil components; for example isopropylmethylphenol, gluconate Chlorhexidine, rivanol, benzalkonium hydrochloride and other fungicides; for example, dobucaine hydrochloride, lidocaine hydrochloride, procaine hydrochloride, tetracaine hydrochloride, bupivacaine hydrochloride, prilocaine hydrochloride Local anesthetics such as caffeine, occaine hydrochloride, mepivacaine hydrochloride, oxycaine; etc .; for example, anti-itch agents such as crotamiton, tartar, Mocthammol, thymol phenolic acid; for example, pepper extract, capsaicin, nony Blood flow enhancers such as vanillyl amide; for example, dexamethasone valerate, dexamethasone valerate acetate, dexamethasone propionate, prednisolone acetate, prednisolone valerate, prednisolone, butyl Hydrocortisone Propionate, Hydrocortisone Acetate, Cortisone Butyrate, Cortisone Acetate, Clobetasone Butyrate, Triamcinolone acetonide, Difluorocortisone valerate, Difluoropregnantine Steroid hormones such as esters, diflurasone acetate, betamethasone dipropionate, ancinald, hasinaide, budesonide, aclomethasone dipropionate; and the pharmaceutically acceptable salts of these (in When the above-mentioned medicine is a salt, it is another salt) and when the above-mentioned medicine is a salt, its free substance can be used alone or in combination of two or more.

於本發明之凝膠製劑中,作為上述藥物之含量,可根據上述藥物之種類及/或凝膠製劑之投予目的而適當調整為可獲得較佳之治療效果之量,若為以通常之投予為目的之量,則不會阻礙上述凝膠基質之白色殘留之產生抑制效果或鱗屑樣物之產生抑制效果。作為此種可獲得較佳之治療效果之藥物之含量,通常例如可列舉相對於上述凝膠基質100質量份成為0.5~3.1質量份之量。又,本發明之凝膠製劑可根據藥物之種類或組合、量,而適當設定使用量或使用次數。 In the gel preparation of the present invention, the content of the above-mentioned drugs can be appropriately adjusted according to the type of the above-mentioned drugs and / or the purpose of administration of the gel preparation to obtain an amount with better therapeutic effect. The intended amount does not hinder the production inhibitory effect of the white residue of the gel matrix or the production inhibitory effect of scale-like substances. As the content of such a drug that can obtain a better therapeutic effect, generally, for example, an amount of 0.5 to 3.1 parts by mass relative to 100 parts by mass of the gel matrix can be mentioned. In addition, the gel preparation of the present invention can appropriately set the amount of use or the number of times of use according to the type, combination, and amount of drugs.

作為本發明之凝膠基質及凝膠製劑之製造方法,並無特別限制,可藉由分別適當地採用公知之凝膠基質及凝膠製劑之製造方法而進行製造。例如,藉由將上述單萜衍生物、上述水溶性高分子、上述滑石、上述醇、上述水、及視需要之上述添加劑混合而製成均勻之凝 膠狀,可獲得目標之凝膠基質。又,藉由將上述凝膠基質與上述藥物混合,或將上述單萜衍生物、上述水溶性高分子、上述滑石、上述醇、上述水、上述藥物、及視需要之上述添加劑混合而製成均勻之凝膠狀,可獲得目標之凝膠製劑。所製造之本發明之凝膠基質及凝膠製劑被填充於管或塑膠製容器、玻璃製容器等中而被包裝。 The method for producing the gel matrix and the gel preparation of the present invention is not particularly limited, and can be produced by appropriately adopting known methods for producing the gel matrix and the gel preparation, respectively. For example, by mixing the above-mentioned monoterpene derivative, the above-mentioned water-soluble polymer, the above-mentioned talc, the above-mentioned alcohol, the above-mentioned water, and, if necessary, the above-mentioned additives, a uniform gel can be made Gelatinous, the target gel matrix can be obtained. Furthermore, it is prepared by mixing the gel matrix with the drug, or mixing the monoterpene derivative, the water-soluble polymer, the talc, the alcohol, the water, the drug, and the additives as needed. Uniform gel form, the target gel preparation can be obtained. The manufactured gel matrix and gel preparation of the present invention are filled in tubes, plastic containers, glass containers, etc., and packaged.

[實施例] [Example]

以下,基於實施例及比較例更加具體地說明本發明,但本發明不限定於以下實施例。再者,於各實施例及比較例中,白色殘留評價試驗及鱗屑樣物評價試驗係分別藉由以下所示之方法進行。 Hereinafter, the present invention will be described more specifically based on examples and comparative examples, but the present invention is not limited to the following examples. In addition, in each Example and Comparative Example, the white residue evaluation test and the scale-like substance evaluation test were performed by the methods shown below, respectively.

(白色殘留評價試驗) (White residue evaluation test)

對於藉由各實施例及比較例所獲得之凝膠基質,首先,分別於健康成年男性(5人)之下臂以成為50cm2之方式塗佈各凝膠基質500mg並使其乾燥。繼而,對於乾燥後之各塗佈部分,將可視認到塗佈部分整體變白之狀態記為「1」,將無法視認到塗佈部分變白之狀態設為「5」,以1~5之5階段評價實施官能評價試驗,將其平均值作為5階段之評價結果。 For the gel matrix obtained in each of the examples and comparative examples, first, 500 mg of each gel matrix was applied to the lower arm of a healthy adult male (5 persons) so as to become 50 cm 2 and dried. Then, for each coated part after drying, the state where the entire coated part is whitened is recorded as "1", and the state where the coated part cannot be recognized as whitened is set to "5", with 1 to 5 In the 5-stage evaluation, a sensory evaluation test was carried out, and the average value was used as the 5-stage evaluation result.

又,分別於健康成年男性之下臂以成為50cm2之方式塗佈各凝膠基質500mg,對於乾燥後之塗佈部分,亦基於下述評價基準進行評價,設為3階段之評價結果: In addition, 500 mg of each gel matrix was applied to the lower arm of a healthy adult male so as to become 50 cm 2 , and the coated portion after drying was also evaluated based on the following evaluation criteria, and set as a three-stage evaluation result:

A:無法視認到塗佈部分變白 A: The coated part cannot be seen as white

B:可視認到塗佈部分之面積之30%以下之範圍變白 B: It can be seen that the area below 30% of the area of the coated part turns white

C:可視認到超過塗佈部分之面積之30%之範圍變白。 C: It can be seen that the area exceeding 30% of the area of the coated part turns white.

進而,於健康成年男性(30人)之左右之一下臂,以成為50cm2之方式塗佈各凝膠基質500mg、於另一下臂以成為50cm2之方式塗佈成為評價基準之基準製劑(含有固定量之滑石、水溶性高分子及醇之凝膠基質)500mg,並使其等乾燥。對於乾燥後之塗佈部分,將可視認 到塗佈部分整體變白之狀態記為「20」,將無法視認到塗佈部分變白之狀態記為「100」,以20、40、60、80及100之5階段評價實施官能評價試驗。求出各凝膠基質之評價值相對於基準製劑之評價值之比例(得分比),將其平均值作為得分評價之結果。 Further, in the healthy adult male (30) about left and right of the arm so as to be applied to each of Embodiment 2 50cm gel matrix 500mg, in another embodiment the lower arm 2 of 50cm so as to be applied to the evaluation criteria become the reference formulation (containing A fixed amount of talc, a water-soluble polymer and a gel matrix of alcohol) 500 mg, and allowed to dry. For the coated part after drying, the state where the entire coated part is whitened is recorded as "20", and the state where the coated part is not recognized as whitened is recorded as "100", with 20, 40, 60, The sensory evaluation test was carried out in the 5-stage evaluation of 80 and 100. The ratio (score ratio) of the evaluation value of each gel matrix to the evaluation value of the reference preparation was obtained, and the average value was used as the result of the score evaluation.

(鱗屑樣物評價試驗) (Evaluation Test of Scale Sample)

對於藉由各實施例及比較例所獲得之凝膠基質,首先,分別於健康成年男性(5人)之下臂以成為50cm2之方式塗佈各凝膠基質500mg並使其乾燥。繼而,對於乾燥後之各塗佈部分,將可視認到於塗佈部分整體鱗狀地殘留有乾燥之凝膠基質之狀態記為「1」,將無法視認到於塗佈部分鱗狀地殘留有乾燥之凝膠基質之狀態記為「5」,以1~5之5階段評價實施官能評價試驗,將其平均值作為5階段之評價結果。 For the gel matrix obtained in each of the examples and comparative examples, first, 500 mg of each gel matrix was applied to the lower arm of a healthy adult male (5 persons) so as to become 50 cm 2 and dried. Then, for each coated portion after drying, the state where the dried gel matrix is visually recognized as squamously remaining on the entire coated portion is denoted as "1", and the scaly remaining on the coated portion cannot be recognized The state of the dried gel matrix was recorded as "5", and the functional evaluation test was carried out in 5 stages of evaluation from 1 to 5, and the average value was taken as the evaluation result of 5 stages.

又,分別於健康成年男性之下臂以成為50cm2之方式塗佈各凝膠基質500mg,對於乾燥後之塗佈部分,亦基於下述評價基準進行評價,設為3階段之評價結果: In addition, 500 mg of each gel matrix was applied to the lower arm of a healthy adult male so as to become 50 cm 2 , and the coated portion after drying was also evaluated based on the following evaluation criteria, and set as a three-stage evaluation result:

A:無法視認到於塗佈部分鱗狀地殘留有乾燥之凝膠基質 A: It is not visible that the dried gel matrix remains scaly on the coated part

B:可視認到於塗佈部分之面積之30%以下之範圍鱗狀地殘留有乾燥之凝膠基質 B: It can be seen that the dried gel matrix remains squamously within a range of 30% or less of the area of the coated part

C:可視認到於超過塗佈部分之面積之30%之範圍鱗狀地殘留有乾燥之凝膠基質。 C: It can be seen that the dried gel matrix remains scaly in a range exceeding 30% of the area of the coated part.

進而,於健康成年男性(30人)之左右之一下臂,以成為50cm2之方式塗佈各凝膠基質500mg、於另一下臂以成為50cm2之方式塗佈成為評價基準之基準製劑(含有固定量之滑石、水溶性高分子及醇之凝膠基質)500mg,並使其等乾燥。對於乾燥後之塗佈部分,將可視認到於塗佈部分整體鱗狀地殘留有乾燥之凝膠基質之狀態記為「20」,將無法視認到於塗佈部分鱗狀地殘留有乾燥之凝膠基質之狀態記為「100」,以20、40、60、80及100之5階段評價實施官能評價試驗。求 出各凝膠基質之評價值相對於基準製劑之評價值之比例(得分比),將其平均值作為得分評價之結果。 Further, in the healthy adult male (30) about left and right of the arm so as to be applied to each of Embodiment 2 50cm gel matrix 500mg, in another embodiment the lower arm 2 of 50cm so as to be applied to the evaluation criteria become the reference formulation (containing A fixed amount of talc, a water-soluble polymer and a gel matrix of alcohol) 500 mg, and allowed to dry. For the coated part after drying, the state where the dried gel matrix can be visually recognized as squamously remaining on the entire coated part is denoted as "20", and it cannot be recognized that the dried part has squamously dried on the coated part The state of the gel matrix was recorded as "100", and the functional evaluation test was conducted in five stages of 20, 40, 60, 80, and 100. The ratio (score ratio) of the evaluation value of each gel matrix to the evaluation value of the reference preparation was obtained, and the average value was used as the result of the score evaluation.

(實施例1) (Example 1)

首先,將羥丙基纖維素(水溶性高分子/商品名:HPC-H,日本曹達股份有限公司製造):3質量份、滑石(體積基準平均粒徑:10μm,松村產業股份有限公司製造):4質量份、3-L-薄荷氧基丙烷-1,2-二醇(商品名:1-薄荷基甘油醚,高砂香料工業股份有限公司製造):0.5質量份、異丙醇(醇):70質量份、及純化水:22.5質量份混合,獲得均勻之凝膠狀之凝膠基質。再者,20℃下之上述羥丙基纖維素之2質量%水溶液之黏度為2,660mPa‧s。 First, hydroxypropyl cellulose (water-soluble polymer / trade name: HPC-H, manufactured by Japan Soda Co., Ltd.): 3 parts by mass, talc (volume-based average particle size: 10 μm, manufactured by Matsumura Industries Co., Ltd.) : 4 parts by mass, 3-L-menthoxypropane-1,2-diol (trade name: 1-menthyl glyceryl ether, manufactured by Takasago Perfume Industry Co., Ltd.): 0.5 parts by mass, isopropyl alcohol (alcohol) : 70 parts by mass, and purified water: 22.5 parts by mass to obtain a uniform gel matrix. Furthermore, the viscosity of the 2% by mass aqueous solution of the above hydroxypropyl cellulose at 20 ° C is 2,660 mPa‧s.

(實施例2~7、實施例9~12、比較例1~2及比較例5~6) (Examples 2-7, Examples 9-12, Comparative Examples 1-2, and Comparative Examples 5-6)

分別將凝膠基質之成分設為表1~2所示之成分,除此以外,以與實施例1相同之方式獲得各凝膠基質。再者,表1中,作為香葉草醇,使用2-反式-3,7-二甲基-2,6-辛二烯-1-醇(商品名:GERANIOL,高砂香料工業股份有限公司製造)。 Each gel matrix was obtained in the same manner as in Example 1 except that the components of the gel matrix were set as the components shown in Tables 1 to 2, respectively. In addition, in Table 1, as geraniol, 2-trans-3,7-dimethyl-2,6-octadien-1-ol (trade name: GERANIOL, Takasago Perfume Industry Co., Ltd.) was used Manufacturing).

(實施例8) (Example 8)

首先,於羥丙基纖維素(水溶性高分子/商品名:HPC-H,日本曹達股份有限公司製造):3質量份、滑石(體積基準平均粒徑:10μm,松村產業股份有限公司製造):4質量份、3-L-薄荷氧基丙烷-1,2-二醇(商品名:1-薄荷基甘油醚,高砂香料工業股份有限公司製造):2.5質量份、異丙醇(醇):75質量份、1-薄荷腦:3質量份、及純化水:11.5質量份中混合雙氯芬酸鈉:1.0質量份(相對於凝膠基質100質量份為1.01質量份),獲得均勻之凝膠狀之凝膠製劑。 First, in hydroxypropyl cellulose (water-soluble polymer / trade name: HPC-H, manufactured by Nippon Soda Co., Ltd.): 3 parts by mass, talc (volume-based average particle size: 10 μm, manufactured by Matsumura Industries Co., Ltd.) : 4 parts by mass, 3-L-menthoxypropane-1,2-diol (trade name: 1-menthyl glyceryl ether, manufactured by Takasago Perfumery Co., Ltd.): 2.5 parts by mass, isopropyl alcohol (alcohol) : 75 parts by mass, 1-menthol: 3 parts by mass, and purified water: 11.5 parts by mass mixed with diclofenac sodium: 1.0 parts by mass (1.01 parts by mass relative to 100 parts by mass of the gel matrix) to obtain a uniform gel The gel preparation.

(比較例3~4) (Comparative examples 3 to 4)

分別將異丙醇設為50質量份(比較例3)、89質量份(比較例4),以凝膠基質之總量成為100質量份之方式調整純化水之量,除此以外, 以與比較例1相同之方式獲得各凝膠基質。 Isopropyl alcohol was set to 50 parts by mass (Comparative Example 3) and 89 parts by mass (Comparative Example 4), and the amount of purified water was adjusted so that the total amount of the gel matrix became 100 parts by mass. Each gel matrix was obtained in the same manner as in Comparative Example 1.

對於藉由實施例1~7及比較例1~2所獲得之凝膠基質,進行白色殘留評價試驗(5階段評價)及鱗屑樣物評價試驗(5階段評價),將其結果與各凝膠基質之成分一併示於表1。 For the gel bases obtained in Examples 1 to 7 and Comparative Examples 1 to 2, white residue evaluation test (5-level evaluation) and scale-like substance evaluation test (5-level evaluation) were performed, and the results were compared with each gel The composition of the matrix is shown in Table 1.

如自表1所示之結果可知,確認到:根據本發明之凝膠基質,可充分地抑制因滑石而引起之白色殘留之產生或因水溶性高分子而引起之鱗屑樣物之產生。又,對於藉由實施例8所獲得之凝膠製劑進行白色殘留評價試驗(3階段評價)及鱗屑樣物評價試驗(3階段評價),結果均為A評價。另一方面,於不含本發明之3-L-薄荷氧基丙烷-1,2-二醇或香葉草醇之凝膠基質(比較例1)、或者使用與該等化合物同樣地為單萜衍生物之1-薄荷腦代替其等之凝膠基質(比較例2)中,白色殘留評價試驗及鱗屑樣物評價試驗之評價均較低,可確認未充分地抑制白色殘留之產生及鱗屑樣物之產生。 As can be seen from the results shown in Table 1, it is confirmed that the gel matrix of the present invention can sufficiently suppress the generation of white residue due to talc or the generation of scale-like substances due to water-soluble polymers. In addition, the whiteness evaluation test (3-level evaluation) and scale-like substance evaluation test (3-level evaluation) of the gel preparation obtained in Example 8 were both A evaluations. On the other hand, in the gel base (Comparative Example 1) which does not contain the 3-L-menthoxypropane-1,2-diol or geraniol of the present invention, or the same as those compounds In the gel matrix (Comparative Example 2) of 1-menthol substituted for terpene derivatives, the evaluation of the white residue evaluation test and the scale-like substance evaluation test are both low, and it can be confirmed that the generation of white residue and scales are not sufficiently suppressed The generation of samples.

分別將對於藉由比較例1、3及4所獲得之凝膠基質進行白色殘留評價試驗(得分評價)之結果示於圖1,將進行鱗屑樣物評價試驗(得分評價)之結果示於圖2。又,將對於藉由實施例9~12及比較例5~6所 獲得之凝膠基質進行白色殘留評價試驗(3階段評價)及鱗屑樣物評價試驗(3階段評價)之結果與各凝膠基質之成分一併示於表2。再者,表2中,亦一併表示對藉由實施例4及5所獲得之凝膠基質進行白色殘留評價試驗(3階段評價)及鱗屑樣物評價試驗(3階段評價)之結果。 The results of the white residue evaluation test (score evaluation) on the gel matrix obtained in Comparative Examples 1, 3, and 4 are shown in FIG. 1, and the results of the scale-like substance evaluation test (score evaluation) are shown in FIG. 2. In addition, by using Examples 9-12 and Comparative Examples 5-6 The obtained gel matrix was subjected to a white residue evaluation test (3-stage evaluation) and scale-like substance evaluation test (3-stage evaluation). The results are shown in Table 2 together with the composition of each gel matrix. In addition, Table 2 also shows the results of the white residue evaluation test (3-level evaluation) and scale-like substance evaluation test (3-level evaluation) performed on the gel matrix obtained in Examples 4 and 5.

如自圖1~2所示之結果可知,於不含本發明之3-L-薄荷氧基丙烷-1,2-二醇或香葉草醇之凝膠基質中,若對以基準製劑為基準之得分比彼此進行比較,則確認到:醇濃度越低,白色殘留評價試驗及鱗屑樣物評價試驗中之得分比越低,若醇濃度較低,則有容易產生白色殘留或鱗屑樣物之傾向。相對於此,如自表2所示結果可知,確認到:根據本發明之凝膠基質,即便醇之濃度相對較低,亦可充分地抑制因滑石而引起之白色殘留之產生或因水溶性高分子而引起之鱗屑樣物之產生,進而與僅將醇之濃度設為高濃度之情形(比較例5~6)相比,可高度地抑制白色殘留之產生或鱗屑樣物之產生。 As can be seen from the results shown in Figures 1-2, in a gel matrix that does not contain 3-L-menthoxypropane-1,2-diol or geraniol of the present invention, if the reference formulation is Comparing the score ratios of the benchmarks with each other, it is confirmed that the lower the alcohol concentration, the lower the score ratio in the white residue evaluation test and the scale-like sample evaluation test. The tendency. In contrast, as can be seen from the results shown in Table 2, it is confirmed that the gel matrix of the present invention can sufficiently suppress the occurrence of white residue caused by talc or water solubility even if the alcohol concentration is relatively low. The generation of scale-like substances caused by the polymer can further suppress the generation of white residues or the scale-like substances compared with the case where only the alcohol concentration is set to a high concentration (Comparative Examples 5 to 6).

[產業上之可利用性] [Industry availability]

如以上之說明,根據本發明,可提供一種可充分地抑制因滑石而引起之白色殘留之產生或因水溶性高分子而引起之鱗屑樣物之產生之凝膠基質、及含有其之凝膠製劑。 As described above, according to the present invention, it is possible to provide a gel matrix capable of sufficiently suppressing the generation of white residue caused by talc or the formation of scale-like substances caused by water-soluble polymers, and a gel containing the same preparation.

Claims (5)

一種凝膠基質,其係含有選自由3-L-薄荷氧基丙烷-1,2-二醇及3,7-二甲基-2,6-辛二烯-1-醇所組成之群中之至少1種單萜衍生物、水溶性高分子、滑石、醇及水者;上述水溶性高分子為選自由水溶性纖維素衍生物及羧基乙烯基聚合物所組成之群,上述水溶性纖維素衍生物為選自由羥乙基纖維素、羥丙基纖維素、甲基纖維素、乙基纖維素、羧甲基纖維素及羥丙基甲基纖維素所組成之群中之至少1種,上述單萜衍生物之含量相對於上述凝膠基質之總質量為0.5~10質量%,上述水溶性高分子之含量相對於上述凝膠基質之總質量為0.5~5.0質量%,上述滑石之含量相對於上述凝膠基質之總質量為1.0~6.0質量%。A gel matrix which is selected from the group consisting of 3-L-menthoxypropane-1,2-diol and 3,7-dimethyl-2,6-octadien-1-ol At least one monoterpene derivative, water-soluble polymer, talc, alcohol, and water; the water-soluble polymer is selected from the group consisting of water-soluble cellulose derivatives and carboxyvinyl polymers, and the water-soluble fiber Element derivatives are at least one selected from the group consisting of hydroxyethyl cellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, carboxymethyl cellulose and hydroxypropyl methyl cellulose The content of the monoterpene derivative is 0.5 to 10% by mass relative to the total mass of the gel matrix, and the content of the water-soluble polymer is 0.5 to 5.0% by mass relative to the total mass of the gel matrix. The content is 1.0 to 6.0% by mass relative to the total mass of the above gel matrix. 如請求項1之凝膠基質,其中上述單萜衍生物之含量相對於上述凝膠基質之總質量為0.75~5.0質量%。The gel matrix according to claim 1, wherein the content of the above monoterpene derivative is 0.75 to 5.0% by mass relative to the total mass of the above gel matrix. 如請求項1或2之凝膠基質,其中上述醇為碳數1~3之醇。The gel matrix according to claim 1 or 2, wherein the alcohol is an alcohol having 1 to 3 carbon atoms. 一種凝膠製劑,其含有如請求項1至3中任一項之凝膠基質、及藥物。A gel preparation containing the gel matrix according to any one of claims 1 to 3, and a medicine. 如請求項4之凝膠製劑,其中上述藥物為雙氯芬酸鈉。The gel preparation according to claim 4, wherein the above drug is diclofenac sodium.
TW104116545A 2014-05-23 2015-05-22 Gel base and gel preparation TWI625130B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014107547 2014-05-23

Publications (2)

Publication Number Publication Date
TW201600111A TW201600111A (en) 2016-01-01
TWI625130B true TWI625130B (en) 2018-06-01

Family

ID=54554107

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104116545A TWI625130B (en) 2014-05-23 2015-05-22 Gel base and gel preparation

Country Status (3)

Country Link
JP (1) JP6148794B2 (en)
TW (1) TWI625130B (en)
WO (1) WO2015178445A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1124014A (en) * 1993-05-19 1996-06-05 久光制药株式会社 Solubilizing agent and external preparation containing the same
JP2011173823A (en) * 2010-02-24 2011-09-08 Hisamitsu Pharmaceut Co Inc Gel preparation
TW201406392A (en) * 2012-06-20 2014-02-16 Hisamitsu Pharmaceutical Co Percutaneous absorption promoter and skin patch comprising same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005015368A (en) * 2003-06-25 2005-01-20 Saga Seiyaku Kk Method for stabilizing pranoprofen-containing aqueous liquid preparation
JP5720240B2 (en) * 2009-12-28 2015-05-20 ライオン株式会社 Topical preparation
JP5778964B2 (en) * 2011-03-31 2015-09-16 小林製薬株式会社 Oily preparation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1124014A (en) * 1993-05-19 1996-06-05 久光制药株式会社 Solubilizing agent and external preparation containing the same
JP2011173823A (en) * 2010-02-24 2011-09-08 Hisamitsu Pharmaceut Co Inc Gel preparation
TW201406392A (en) * 2012-06-20 2014-02-16 Hisamitsu Pharmaceutical Co Percutaneous absorption promoter and skin patch comprising same

Also Published As

Publication number Publication date
WO2015178445A1 (en) 2015-11-26
JP6148794B2 (en) 2017-06-14
JPWO2015178445A1 (en) 2017-04-20
TW201600111A (en) 2016-01-01

Similar Documents

Publication Publication Date Title
JP4170751B2 (en) Antifungal nail polish composition
JP6503303B2 (en) Pharmaceutical composition for the treatment of fungal infections
JP2018021002A (en) Pharmaceutical preparation containing loxoprofen
JP6887895B2 (en) Topical composition
JP2021113221A (en) Pharmaceutical preparation containing loxoprofen
JP2020073615A (en) Pharmaceutical preparation containing loxoprofen
JP2011173823A (en) Gel preparation
US20030059446A1 (en) Physically stable sprayable gel composition
JP2019081755A (en) Composition
JP6252481B2 (en) Mucosal ointment
JP6765299B2 (en) Aqueous formulation
TWI625130B (en) Gel base and gel preparation
KR102253063B1 (en) A stick type composition for reducing pain and method for preparing the same
HU200914B (en) Process for producing new medical dosage unit suitable for local treatment of fungus infection of nails
CA2845258A1 (en) Method for preparing metered dose sprayed inhaler for treating respiratory disease
JP2017197537A (en) Pharmaceutical preparation comprising loxoprofen
JP6360795B2 (en) Oral preparation
JP2018052836A (en) External composition
JP6514757B2 (en) Nasal composition
JP2013519695A5 (en)
JP5999875B2 (en) Gel-like pharmaceutical composition
JP7190981B2 (en) gel composition
JP7295273B2 (en) A topical pharmaceutical composition in the form of an aqueous gel containing at least amitriptyline
JP2004161625A (en) Aqueous sticklike external preparation for treating skin disease
JP6929339B2 (en) Topical composition